TC Biopharm (Holdings) Plc TCBP
0.50 USD 0.00 (+0.00%)
At closeMar 21, 2025, 4:00 PM EDT
0.50 Day range 1.51
0.436 52-week range 41.50
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 5.22M
- EPS (ttm)
- -294.87
- Shares out
- 8.21M
- Forward P/E
- -0.14
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 5.90M
- Avg volume
- 1.69M
- Open
- 1.51
- Previous close
- 0.50
- Day's range
- 0.50 – 1.51
- 52-week range
- 0.436 – 41.50
- Beta
- 0.25
- Price target
- 3.00 (+500.0%)
- Earnings date
- May 6, 2024
No chart data for this range yet.
Key statistics
- Enterprise value
- 59.49M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -6.85M
- Total cash
- 980.96K
- Total debt
- 1.73M
- Return on equity
- -1217.48%
- Short % of float
- 6.99%
- 50-day average
- 1.47
- 200-day average
- 7.74
Analyst view
Price target (mean) 3.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
May 6, 2024
Expected May 6, 2024. Consensus EPS estimate 0.00.
Financials — quick view
TCBP Revenue — quarterly 0
TCBP Net income — quarterly -1.99M
TCBP EPS — quarterly 96.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2024 | Dec 1, 2023 | -14.00 | — | — | — |
| May 12, 2023 | Dec 1, 2022 | -5.58 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- tcbiopharm.com
News
TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient 
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Friday's Intraday Session 
TCBP Announces Transition from Nasdaq to OTC Markets 
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead 
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company 
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum 
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial 
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial 
TCBP to Implement ADS Ratio Change
Your note
Sign in to keep a note on TCBP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FNY Investment Advisers, LLC | 0.10% | 8,200 | 5.21K | Sep 29, 2024 |
| SignatureFD, LLC | 0.01% | 492 | 312 | Sep 29, 2024 |
| New England Capital Financial Advisors LLC | 0.00% | 201 | 127 | Sep 29, 2024 |
| Harbour Investments, Inc. | 0.00% | 236 | 150 | Sep 29, 2024 |
| Sanctuary Wealth Management, L.L.C. | 0.00% | 12 | 7 | Sep 29, 2024 |
| Rhumbline Advisers | 0.00% | 83 | 52 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Trust For Professional Managers-PMC Diversified Equity Fund | 0.05% | 19,068 | 12.13K | Aug 30, 2022 |